NCT01658878 study (Table 2) showed that blocking simultaneously both PD-1/PD-L1 and CTLA-4 with Nivolumab and Ipilimumab respectively, an average ORR of 31% and an acceptable safety profile were produced in Sorafenib-treated advanced HCC patients. This evidence concerns the gene CD274 and hepatocellular carcinoma.